280BIO

The KRAS oncogene is frequently mutated in lung, colorectal and pancreatic cancers. This patient journey infographic shows that after the first-line of treatment, patients can receive a series of other treatments for their cancer. The level of response is mixed, patients’ relapse and/or patient’s tumors are prone to molecular change over time; 280Bio meets the unmet medical need for patients with RAS mutations.

Designed while employed at Fassino/Design.

Back to Information Design